These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 21532567)

  • 1. Priorities in Parkinson's disease research.
    Meissner WG; Frasier M; Gasser T; Goetz CG; Lozano A; Piccini P; Obeso JA; Rascol O; Schapira A; Voon V; Weiner DM; Tison F; Bezard E
    Nat Rev Drug Discov; 2011 May; 10(5):377-93. PubMed ID: 21532567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential therapeutic targets for Parkinson's disease.
    Stoessl J
    Expert Opin Ther Targets; 2008 Apr; 12(4):425-36. PubMed ID: 18348679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers of Parkinson's disease: present and future.
    Miller DB; O'Callaghan JP
    Metabolism; 2015 Mar; 64(3 Suppl 1):S40-6. PubMed ID: 25510818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in drug development for Parkinson's disease: present status.
    Harikrishna Reddy D; Misra S; Medhi B
    Pharmacology; 2014; 93(5-6):260-71. PubMed ID: 25096413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Targets for Parkinson's Disease: Addressing Different Therapeutic Paradigms and Conundrums.
    Rane P; Sarmah D; Bhute S; Kaur H; Goswami A; Kalia K; Borah A; Dave KR; Sharma N; Bhattacharya P
    ACS Chem Neurosci; 2019 Jan; 10(1):44-57. PubMed ID: 29957921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and emerging therapeutic targets for Parkinson's disease.
    Pingale T; Gupta GL
    Metab Brain Dis; 2021 Jan; 36(1):13-27. PubMed ID: 33090348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease modification in Parkinson's disease.
    Henchcliffe C; Severt WL
    Drugs Aging; 2011 Aug; 28(8):605-15. PubMed ID: 21812497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease.
    Radad K; Gille G; Rausch WD
    Pharmacol Rep; 2005; 57(6):701-12. PubMed ID: 16382188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of Parkinson's disease.
    Lew M
    Pharmacotherapy; 2007 Dec; 27(12 Pt 2):155S-160S. PubMed ID: 18041935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New treatments for the motor symptoms of Parkinson's disease.
    Vijverman AC; Fox SH
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):761-77. PubMed ID: 25318835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Future drug targets for Parkinson's disease].
    Hirsch EC
    Bull Acad Natl Med; 2012 Oct; 196(7):1369-77; discussion 1377-9. PubMed ID: 23815021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glutamate receptors as therapeutic targets for Parkinson's disease.
    Johnson KA; Conn PJ; Niswender CM
    CNS Neurol Disord Drug Targets; 2009 Dec; 8(6):475-91. PubMed ID: 19702565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. alpha-Synuclein: a therapeutic target for Parkinson's disease?
    Maguire-Zeiss KA
    Pharmacol Res; 2008; 58(5-6):271-80. PubMed ID: 18840530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New directions in the drug treatment of Parkinson's disease.
    Montastruc JL; Rascol O; Senard JM
    Drugs Aging; 1996 Sep; 9(3):169-84. PubMed ID: 8877311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bee venom for the treatment of Parkinson's disease: How far is it possible?
    Awad K; Abushouk AI; AbdelKarim AH; Mohammed M; Negida A; Shalash AS
    Biomed Pharmacother; 2017 Jul; 91():295-302. PubMed ID: 28477460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological therapy of Parkinson's disease: current options and new avenues.
    Simola N; Pinna A; Fenu S
    Recent Pat CNS Drug Discov; 2010 Nov; 5(3):221-38. PubMed ID: 20726838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous drug delivery in Parkinson's disease.
    Senek M; Nyholm D
    CNS Drugs; 2014 Jan; 28(1):19-27. PubMed ID: 24323838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are dopamine receptor agonists neuroprotective in Parkinson's disease?
    Le WD; Jankovic J
    Drugs Aging; 2001; 18(6):389-96. PubMed ID: 11419913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
    Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
    Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives.
    Sarkar S; Raymick J; Imam S
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27338353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.